Abstract: Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.
Type:
Application
Filed:
April 6, 2010
Publication date:
November 4, 2010
Applicant:
EISAI INC.
Inventors:
Sergei BELYAKOV, Bridget DUVALL, Dana FERRARIS, Gregory HAMILTON, Mark VAAL
Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
Type:
Application
Filed:
April 6, 2010
Publication date:
November 4, 2010
Applicant:
EISAI INC.
Inventors:
Sergei BELYAKOV, Bridget DUVALL, Dana FERRARIS, Gregory HAMILTON, Mark VAAL
Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
Type:
Application
Filed:
April 6, 2010
Publication date:
November 4, 2010
Applicant:
EISAI INC.
Inventors:
Sergei BELYAKOV, Bridget DUVALL, Dana FERRARIS, Gregory HAMILTON, Mark VAAL
Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
Type:
Application
Filed:
January 22, 2010
Publication date:
October 21, 2010
Applicant:
Eisai Inc.
Inventors:
Keith Branham, Mahesh V. Chaubal, James P. English, Donna Hall, Zhong Zhao
Abstract: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
Type:
Application
Filed:
June 18, 2010
Publication date:
October 7, 2010
Applicant:
Eisai Inc.
Inventors:
Vincent J. Kalish, Jie Zhang, Weizheng Xu, Jia-He Li, Amy Dongxia Xing, Qun Liu
Abstract: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
Type:
Grant
Filed:
August 13, 2009
Date of Patent:
July 6, 2010
Assignee:
Eisai Inc.
Inventors:
Vincent Kalish, Jie Zhang, Weizheng Xu, Jia-He Li, Amy D. Xing, Qun Liu
Abstract: Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.
Type:
Application
Filed:
December 7, 2009
Publication date:
June 17, 2010
Applicant:
Eisai Inc.
Inventors:
V. Suzanne Klimberg, Robert G. Petit, II, Edward C. Shinal
Abstract: Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.
Type:
Grant
Filed:
August 1, 2003
Date of Patent:
May 4, 2010
Assignee:
Eisai Inc.
Inventors:
V. Suzanne Klimberg, Robert G. Petit, II, Edward C. Shinal
Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
Type:
Grant
Filed:
January 16, 2009
Date of Patent:
March 9, 2010
Assignee:
Eisai Inc.
Inventors:
Keith Branham, Mahesh V. Chaubal, James P. English, Donna Hall, Zhong Zhao
Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
Abstract: The invention is directed to the use of a pharmaceutical composition comprising an effective amount of zonisamide or a pharmaceutically acceptable salt thereof to treat tremors, such as rest tremors or action tremors. Tremors may include kinetic tremor, essential tremor, severe essential tremor, postural tremor, drug-induced tremor, toxic tremor, primary orthostatic tremor, dystonic tremor, neuropathic tremor, and cerebellar tremor. The use of zonisamide in the methods of the invention reduce adverse side effects of other drugs that are used to treat tremors. Zonisamide or a pharmaceutically acceptable salt thereof can also be used in conjunction with other therapeutic agents commonly used to treat tremors, thus enhancing the therapeutic effect of treating tremors.
Abstract: The present invention is directed to a method of treating action tremor or severe essential tremor. Action tremor includes essential tremor, postural tremor, drug-induced or toxic tremor, primary orthostatic tremor, dystonic tremor, neuropathic tremor, and cerebellar tremor. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of zonisamide, or a pharmaceutically acceptable salt thereof. The methods of the present invention are useful in reducing symptoms of tremor. The compounds of the present method can also be used in conjunction with other therapeutic agents commonly used to treat tremor thus enhancing the therapeutic effect of treating tremor.